The Association of Community Cancer Centers has conducted a national multi-phase effort to provide guidance on key issues related to the optimization of care for patients diagnosed with stages III and IV NSCLC.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
